Replay available

Ekso Bionics Holdings, Inc. (EKSO) Q2 2024 Earnings Call

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) Q2 2024 earnings conference call, held 2024-07-29. Replay captured from the company's public earnings webcast.

Mon, July 29, 2024 at 4:30 PMendedReplay
Ekso Bionics Holdings, Inc. (EKSO) Q2 2024 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

ExoBionics Representative

Investor Relations

Scott Davis

Chief Executive Officer

Jerome Wong

Chief Financial Officer

Ben Hainor

Representative, Lake Street Capital Markets

Lee Chen

Representative, HC Brainwhite

Replay transcript excerpt

Greetings, and welcome to the Exobionics Q2 2024 Financial Results Call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Matt Steinberg with FIN Partners. Thank you, Matt. You may begin. Thank you, Operator, and thank you all for participating in today's call. Joining me from ExoBionics are Scott Davis, Chief Executive Officer, and Jerome Wong, Chief Financial Officer. Earlier today, ExoBionics released financial results for the quarter ended June 30, 2024. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements, including statements regarding our business strategy, future financial or operating expectations, or our expectations of the regulatory landscape governing our products and operations are based upon management's current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these stat...

More from Ekso Bionics Holdings, Inc.